A new dawn for clinical trial management
It’s time for pharma to take a 360-degree view of its clinical trial data and step into the future with near real-time trial management.
The pharmaceutical industry faces an important inflection point in its approach to clinical trials and it’s one that COVID-19 has thrown into even sharper relief.
The last great change for studies was the advent in the early 2000s of electronic data capture (EDC). At the time there was a significant amount of resistance to EDC, but now it’s rare to hear about the collection of trial results using paper in all but the occasional single site investigator study.
Now, the major advance that’s available to pharmaceutical companies is in the amount and range of data they have access to and how it can be applied to the risk-based monitoring and remote monitoring of studies.